| scholarly article | Q13442814 |
| P2093 | author name string | Trudo Lemmens | |
| Shannon Gibson | |||
| Hamid R Raziee | |||
| P2860 | cites work | Pharmaceutical marketing and the invention of the medical consumer | Q33238998 |
| Follow-on biologics: a new play for big pharma: Healthcare 2010. | Q33943453 | ||
| Phase IV of Drug Development. | Q34028072 | ||
| The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? | Q34090111 | ||
| Accelerating orphan drug development | Q34152583 | ||
| Pricing and reimbursement of orphan drugs: the need for more transparency | Q34193502 | ||
| The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts | Q34310173 | ||
| Clinical trials in the era of personalized oncology | Q35555963 | ||
| Can pharmacogenetics help rescue drugs withdrawn from the market? | Q36596713 | ||
| The prospects for "personalized medicine" in drug development and drug therapy | Q36720897 | ||
| Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers | Q36767490 | ||
| Exploring emerging technologies using metaphors--a study of orphan drugs and pharmacogenomics | Q37097521 | ||
| The use of genomics in clinical trial design | Q37284262 | ||
| A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment | Q37411548 | ||
| Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine | Q37551901 | ||
| Cancer biomarkers: selecting the right drug for the right patient | Q37982927 | ||
| Overcoming regulatory and economic challenges facing pharmacogenomics | Q37988672 | ||
| Niche markets and evidence assessment in transition: a critical review of proposed drug reforms | Q38212874 | ||
| Forty years of translational cancer research | Q39617452 | ||
| The future costs, risks and rewards of drug development: the economics of pharmacogenomics | Q39964586 | ||
| A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry | Q40139934 | ||
| The thin line between hope and hype in biomarker research | Q42697824 | ||
| Bye, bye blockbusters, hello niche busters | Q42861150 | ||
| Big pharma moves from 'blockbusters' to 'niche busters' | Q44136078 | ||
| Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective | Q44315880 | ||
| When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada | Q45754296 | ||
| Small studies: strengths and limitations | Q46269165 | ||
| Rebuilding the R&D engine in big pharma | Q47648392 | ||
| Potential interactions of the Orphan Drug Act and pharmacogenomics: a flood of orphan drugs and abuses? | Q48475758 | ||
| European regulation on orphan medicinal products: 10 years of experience and future perspectives. | Q51711644 | ||
| Will Lower Drug Prices Jeopardize Drug Research? A Policy Fact Sheet | Q57989237 | ||
| Potential of adaptive clinical trial designs in pharmacogenetic research | Q63865799 | ||
| What will it take to reap the clinical benefits of pharmacogenomics? | Q79443458 | ||
| Evaluating the efficiency of targeted designs for randomized clinical trials | Q80901366 | ||
| Pharmaceutical research and development: what do we get for all that money? | Q84750358 | ||
| Drug development: Innovation or imitation deficit? | Q84938579 | ||
| Personalized medicine: the absence of 'model-changing' financial incentives | Q88790423 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | personalized medicine | Q2072214 |
| P304 | page(s) | 3-27 | |
| P577 | publication date | 2015-03-01 | |
| P1433 | published in | World Medical & Health Policy | Q15716518 |
| P1476 | title | Why the Shift? Taking a Closer Look at the Growing Interest in Niche Markets and Personalized Medicine | |
| P478 | volume | 7 |
Search more.